Exertional rhabdomyolysis: A clinical review with a focus on genetic influences

Journal of Clinical Neuromuscular Disease

Volumn 13, Issue 3, 2012, Pages 122-136

  Landau, Mark E ^a   Kenney, Kimbra ^a   Deuster, Patricia ^b   Campbell, William ^a  

^a Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

creatine kinase; malignant hyperthermia; myoglobinuria; myopathy; rhabdomyolysis

Indexed keywords

ADENOSINE MONOPHOSPHATE DEAMINASE; ADENOSINE TRIPHOSPHATE; ALPHA ACTININ 3; CARNITINE PALMITOYLTRANSFERASE; CREATINE KINASE; CREATINE KINASE ISOENZYME; DIPEPTIDYL CARBOXYPEPTIDASE; GLYCOGEN PHOSPHORYLASE; HEAT SHOCK PROTEIN; INTERLEUKIN 6; MYOSIN LIGHT CHAIN KINASE;

ACUTE KIDNEY FAILURE; ADENOSINE MONOPHOSPHATE DEAMINASE DEFICIENCY; CARNITINE PALMITOYL TRANSFERASE DEFICIENCY; CREATINE KINASE BLOOD LEVEL; DISEASE ASSOCIATION; DNA POLYMORPHISM; ELECTRODIAGNOSIS; ENZYME DEFICIENCY; EXERCISE; EXERTIONAL RHABDOMYOLYSIS; FLUID THERAPY; GENE MUTATION; GENETIC VARIABILITY; GLYCOGEN STORAGE DISEASE TYPE 5; HEAT INJURY; HEAT INTOLERANCE; HEREDITY; HUMAN; MALIGNANT HYPERTHERMIA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; REVIEW; RHABDOMYOLYSIS;

ANIMALS; BODY MASS INDEX; CARNITINE O-PALMITOYLTRANSFERASE; CREATINE KINASE; EXERCISE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MILITARY PERSONNEL; MUTATION; PEPTIDYL-DIPEPTIDASE A; RHABDOMYOLYSIS;

EID: 84857887138     PISSN: 15220443     EISSN: 15371611     Source Type: Journal    
DOI: 10.1097/CND.0b013e31822721ca     Document Type: Review

References (93)

1. Tsai CN, Liu MF, Lin TS, et al. Rhabdomyolysis and acute renal failure in a polymyositis patient. Mod Rheumatol. 2004;14:422-423.
2. Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: An evaluation of 475 hospitalized patients. Medicine (Baltimore). 2005;84:377-385.
3. Warren JS, Blumbergs PC, Thompson PD. Rhabdomyolysis: A review. Muscle Nerve. 2002;25:332-347.
4. Laforêt P, Vianey-Saban C. Disorders of muscle lipid metabolism: Diagnostic and therapeutic challenges. Neuromuscul Disord. 2010;20:693-700.
5. Garry JP, McShane JM. Postcompetition elevation of muscle enzyme levels in professional football players. MedGenMed. 2000;2:E4.
6. Wakabayashi Y, Kikuno T, Ohwada T, et al. Rapid fall in blood myoglobin in massive rhabdomyolysis and acute renal failure. Intensive Care Med. 1994;20: 109-112.
7. Olerud JE, Homer LD, Carroll HW. Incidence of acute exertional rhabdomyolysis. Serum myoglobin and enzyme levels as indicators of muscle injury. Arch Intern Med. 1976;136:692-697.
8. Chevion S, Moran DS, Heled Y, et al. Plasma antioxidant status and cell injury after severe physical exercise. Proc Natl Acad Sci U S A. 2003; 100:5119-5123.
9. Clarkson PM, Kearns AK, Rouzier P, et al. Serum creatine kinase levels and renal function measures in exertional muscle damage. Med Sci Sports Exerc. 2006;38:623-627.
10. Kenney K, Gonzalez RS, Landau ME, et al. Exertional rhabdomyolysis in military recruits: Are the current CK diagnostic levels valid? [Abstract]. Ann Neurol. 2009;66(suppl 13):S25.
11. Nardin RA, Zarrin AR, Horowitz GL, et al. Effect of newly proposed CK reference limits on neuromuscular diagnosis. Muscle Nerve. 2009;39:494-497.
12. Meltzer H. Factors affecting serum creatine phosphokinase levels in the general population: The role of race, activity and sex. Clin Chim Acta. 1971;33: 165-172.
13. Gitin EL, Demos MA. Acute exertional rhabdomyolysis: A syndrome of increasing importance to the military physician. Mil Med. 1974;139: 33-36.
14. Gitin EL, Demos MA, Adams JF. Military concern with myoglobinuria. Ann Intern Med. 1972;77:659.
15. Greenberg J, Arneson L. Exertional rhabdomyolysis with myoglobinuria in a large group of military trainees. Neurology. 1967;17:216-222.
16. Smith RF. Exertional rhabdomyolysis in Naval Officer Candidates. Arch Intern Med. 1968;121:313-319.
17. Aizawa H, Morita K, Minami H, et al. Exertional rhabdomyolysis as a result of strenuous military training. J Neurol Sci. 1995;132:239-240.
18. Frucht M. Challenge, 110 deep knee bends; reward, rhabdomyolysis. N Engl J Med. 1994;330:1620-1621.
19. Mahakkanukrauh A, Sangchan A, Mootsikapun P. Exertional rhabdomyolysis following excessive exercise of university freshman cheer-training. J Med Assoc Thai. 2003;86:789-792.
20. Juray RM. Exertional rhabdomyolysis in unsupervised exercises in a correctional setting: A case study. Urol Nurs. 2005;25:117-119.
21. Kruse DH. -Tyson squats- as a cause of rhabdomyolysis. J Emerg Nurs. 1998;24:116-117.
22. Granata A, Lo Piccolo G, Ruffo C, et al. Rhabdomyolysis after body building exercise. Nephron. 2002;91:354-355.
23. Springer BL, Clarkson PM. Two cases of exertional rhabdomyolysis precipitated by personal trainers. Med Sci Sports Exerc. 2003;35:1499-1502.
24. Howenstine JA. Exertion-induced myoglobinuria and hemoglobinuria: Simulation of acute glomerulonephritis. JAMA. 1960;173:493-499.
25. Clarkson PM. Case report of exertional rhabdomyolysis in a 12-year-old boy. Med Sci Sports Exerc. 2006; 38:197-200.
26. Singhal PC, Chugh KS, Gulati DR. Myoglobinuria and renal failure after status epilepticus. Neurology. 1978;28:200-201.
27. Shank ES, Muth CM. Diver with decompression injury, elevation of serum transaminase levels, and rhabdomyolysis. Ann Emerg Med. 2001;37:533-536.
28. Young IM, Thomson K. Spinning-induced rhabdomyolysis: A case report. Eur J Emerg Med. 2004;11: 358-359.
29. Kerle, KK, Nishimura K. Exertional collapse and sudden death associated with sickle cell trait: A literature review. Am Fam Physician. 1996;54: 237-240.
30. Sandhu RS, Como JJ, Scalea TS, et al. Renal failure and exercise-induced rhabdomyolysis in patients taking performance-enhancing compounds. J Trauma. 2002;53:761-763.
31. Lindholm A, Johansson HE, Kjaersgaard P. Acute rhabdomyolysis (-tying-up-) in standardbred horses. A morphological and biochemical study. Acta Vet Scand. 1974;15:325-339.
32. Piercy RJ, Hinchcliff KW, Morley PS, et al. Vitamin E and exertional rhabdomyolysis during endurance sled dog racing. Neuromuscul Disord. 2001;11:278-286.
33. Valberg SJ, Mickelson JR, Gallant EM, et al. Exertional rhabdomyolysis in quarter horses and thoroughbreds: One syndrome, multiple aetiologies. Equine Vet J Suppl. 1999;30:533-538.
34. Hinchcliff KW, Shaw LC, Vukich NS, et al. Effect of distance traveled and speed of racing on body weight and serum enzyme activity of sled dogs competing in a long-distance race. J Am Vet Med Assoc. 1998;213:639-644.
35. Burr JR, Reinhart GA, Swenson RA, et al. Serum biochemical values in sled dogs before and after competing in long-distance races. J Am Vet Med Assoc. 1997;211:175-179.
36. de Meijer AR, Fikkers BG, de Keijzer MH, et al. Serum creatine kinase as predictor of clinical course in rhabdomyolysis: A 5-year intensive care survey. Intensive Care Med. 2003;29:1121-1125.
37. Veenstra J, Smit WM, Krediet RT, et al. Relationship between elevated creatine phosphokinase and the clinical spectrum of rhabdomyolysis. Nephrol Dial Transplant. 1994;9:637-641.
38. Sinert R, Kohl L, Rainone T, Scalea T. Exerciseinduced rhabdomyolysis. Ann Emerg Med. 1994;23: 1301-1306.
39. Alpers JP, Jones LK. Natural history of exertional rhabdomyolysis: A population based analysis. Muscle Nerve. 2010;42:487-491.
40. Carter R, Cheuvront SN, Williams JO, et al. Epidemiology of hospitalizations and deaths from heat illness in soldiers. Med Sci Sports Exerc. 2005;37:1338-1344.
41. Hsu YD, Lee WH, Chang MK, et al. Blood lactate threshold and type II fibre predominance in patients with exertional heatstroke. J Neurol Neurosurg Psychiatry. 1997;62:182-187.
42. Rusyniak DE, Sprague JE. Toxin-induced hyperthermic syndromes. Med Clin N Am. 2005;89:1277-1296.
43. Tobin JR, Jason DR, Challa VR, et al. Malignant hyperthermia and apparent heat stroke. JAMA. 2001; 286:168-169.
44. Davis M, Brown R, Dickson A, et al. Malignant hyperthermia associated with exercise-induced rhabdomyolysis or congenital abnormalities and a novel RYR1 mutation in New Zealand and Australian pedigrees. Br J Anaesth. 2002;88:508-515.
45. Kochling A, Wappler F, Winkler G, et al. Rhabdomyolysis following severe physical exercise in a patient with predisposition to malignant hyperthermia. Anaesth Intensive Care. 1998;26:315-318.
46. McCarthy T. Mutation screening of the ryanodine receptor gene in malignant hyperthermia. In: Scholz J, Schulte AM, Esch J, eds. Malignant Hyperthermia. Lengerich, Germany: Pabst Science Publishers; 2000: 200-211.
47. Wappler F, Fiege M, Steinfath M, et al. Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis. Anesthesiology. 2001;94:95-100.
48. Giannoglou GD, Chatzizisis YS, Misirli G. The syndrome of rhabdomyolysis: Pathophysiology and diagnosis. Eur J Intern Med. 2007;18:90-100.
49. Bonnefont JP, Demaugre F, Prip-Buus C, et al. Carnitine palmitoyltransferase deficiencies. Mol Genet Metab. 1999;68:424-440.
50. Taroni F, Verderio E, Dworzak F, et al. Identification of a common mutation in the carnitine palmitoyltransferase II gene in familial recurrent myoglobinuria patients. Nat Genet. 1993;4:314-320.
51. Vladutiu GD, Hogan K, Saponara I, et al. Carnitine palmitoyl transferase deficiency in malignant hyperthermia. Muscle Nerve. 1993;16:485-491.
52. Martinuzzi A, Sartori E, Fanin M, et al. Phenotype modulators in myophosphorylase deficiency. Ann Neurol. 2003;53:497-502.
53. Wolfe GI, Baker NS, Haller RG, et al. McArdle s disease presenting with asymmetric, late-onset arm weakness. Muscle Nerve. 2000;23:641-645.
54. Andreu AL, Nogales-Gadea G, Cassandrini D, et al. McArdle disease: Molecular genetic update. Acta Myologica. 2007;26:53-57.
55. Tsujino S, Shanske S, DiMauro S. Molecular genetic heterogeneity of myophosphorylase deficiency (McArdle s disease). N Engl J Med. 1993;329:241-245.
56. Martin MA, Rubio JC, Buchbinder J, et al. Molecular heterogeneity of myophosphorylase deficiency (McArdle s disease): A genotype-phenotype correlation study. Ann Neurol. 2001;50:574-581.
57. Morisaki T, Gross M, Morisaki H, et al. Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc Natl Acad Sci U S A. 1992;89:6457-6461.
58. Norman B, Mahnke-Zizelman DK, Vallis A, et al. Genetic and other determinants of AMP deaminase activity in healthy adult skeletal muscle. J Appl Physiol. 1998;85:1273-1278.
59. Isackson PJ, Bujnicki H, Harding CO, et al. Myoadenylate deaminase deficiency caused by alternative splicing due to a novel intronic mutation in the AMPD1 gene. Mol Genet Metab. 2005;86:250-256.
60. Rico-Sanz J, Rankinen T, Joanisse DR, et al. Associations between cardiorespiratory responses to exercise and the C34T AMPD1 gene polymorphism in the HERITAGE Family Study. Physiol Genomics. 2003; 14:161-166.
61. Hanisch F, Joshi P, Zierz S. AMP deaminase deficiency in skeletal muscle is unlikely to be of clinical l relevance. J Neurol. 2008;255:318-322.
62. Sambuughin N, Holley H, Muldoon S, et al. Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the North American population. Anesthesiology. 2005;102:515-521.
63. Sambuughin N, Capacchione J, Blokhin A, et al. The ryanodine receptor type 1 gene variants in African American men with exertional rhabdomyolysis and malignant hyperthermia susceptibility. Clin Genet. 2009;76:564-568.
64. Clarkson PM, Hoffman EP, Zambraski E, et al. ACTN3 and MLCK genotype associations with exertional muscle damage. J Appl Physiol. 2005;99:564-569.
65. Heled Y, Moran DS, Mendel L, et al. Human ACE I/D polymorphism is associated with individual differences in exercise heat tolerance. J Appl Physiol. 2004;97:72-76.
66. Jones A, Montgomery HE, Woods DR. Human performance: A role for the ACE genotype? Exerc Sport Sci Rev. 2002;30:184-190.
67. Macarthur DG, North KN. Genes and human elite athletic performance. Hum Genet. 2005;116:331-339.
68. Rivera MA, Dionne FT, Simoneau JA, et al. Musclespecific creatine kinase gene polymorphism and VO2max in the HERITAGE Family Study. Med Sci Sports Exerc. 1997;29:1311-1317.
69. Heled Y, Bloom MS, Wu TJ, et al. CK-MM and ACE genotypes and physiological prediction of the creatine kinase response to exercise. J Appl Physiol. 2007;103: 504-510.
70. Rankinen T, Perusse L, Gagnon J, et al. Angiotensinconverting enzyme ID polymorphism and fitness phenotype in the HERITAGE Family Study. J Appl Physiol. 2000;88:1029-1035.
71. Woods DR, World M, Rayson MP, et al. Endurance enhancement related to the human angiotensin Iconverting enzyme I-D polymorphism is not due to differences in the cardiorespiratory response to training. Eur J Appl Physiol. 2002;86:240-244.
72. Yang N, MacArthur DG, Gulbin JP, et al. ACTN3 genotype is associated with human elite athletic performance. Am J Hum Genet. 2003;73:627-631.
73. Echegaray M, Rivera MA. Role of creatine kinase isoenzymes on muscular and cardiorespiratory endurance: Genetic and molecular evidence. Sports Med. 2001;31:919-934.
74. Schneider EM, Niess AM, Lorenz I, et al. Inducible HSP70 expression analysis after heat and physical exercise: Transcriptional, protein expression, and subcellular localization. Ann N YAcad Sci. 2002;973: 8-12.
75. Coerwinkel-Driessen M, Schepens J, van Zandvoort P, et al. NcoI RFLP at the creatine kinase-muscle type gene locus (CKMM, chromosome 19). Nucleic Acids Res. 1988;16:8743.
76. Steeghs K, Benders A, Oerlemans F, et al. Altered Ca2+ responses in muscles with combined mitochondrial and cytosolic creatine kinase deficiencies. Cell. 1997;89:93-103.
77. Bouchard C, Chagnon M, Thibault MC, et al. Muscle genetic variants and relationship with performance and trainability. Med Sci Sports Exerc. 1989;21:71-77.
78. Morton JP, Kayani AC, McArdle A, et al. The exercisenduced stress response of skeletal muscle, with specific emphasis on humans. Sports Med. 2009;39: 643-662.
79. Puntschart A, Vogt M, Widmer HR, et al. HSP70 expression in human skeletal muscle after exercise. Acta Physiol Scand. 1996;157:411-417.
80. Thompson HS, Maynard EB, Morales ER, et al. Exercise-induced HSP27, HSP70 and MAPK responses in human skeletal muscle. Acta Physiol Scand. 2003;178:61-72.
81. Heled Y, Contreras-Sesvold C, Zeno S, et al.Do heat shock protein 70-2 and interleukin-6 genes contribute to exercise-induced increases in creatine kinase? Presentation at the 55th annual American College of Sports Medicine, Indianapolis, IN, May 2008.
82. Febbraio MA, Pederson BK. Muscle derived interleukin- 6: Mechanisms for activation and possible biological roles. FASEB. 2002;16:1335-1347.
83. Pedersen BK, Fischer CP. Physiological roles of muscle-derived interleukin-6 in response to exercise. Curr Opin Clin Nutr Metab Care. 2007;10: 265-271.
84. Yamin C, Duarte JA, Oliveira JM, et al. IL6 (-174) and TNFA (-308) promoter polymorphisms are associated with systemic creatine kinase response to eccentric exercise. Eur J Appl Physiol. 2008;104:579-586.
85. Fernandez C, de Paula AM, Figarella-Branger D, et al. Diagnostic evaluation of clinically normal subjects with chronic hyperCKemia. Neurology. 2006;66: 1585-1587.
86. Prelle A, Tancredi L, Sciacco M, et al. Retrospective study of a large population of patients with asymptomatic or minimally symptomatic raised serum creatine kinase levels. J Neurol. 2002;249:305-411.
87. Dabby R, Sadeh M, Herman O, et al. Asymptomatic or minimally symptomatic hyperCKemia: Histopathologic correlates. Isr Med Assoc J. 2006;8:110-113.
88. Reijneveld JC, Notermans NC, Linssen WH, et al. Benign prognosis in idiopathic hyper-CK-emia. Muscle Nerve. 2000;23:575-579.
89. Joy JL, Oh SJ. Asymptomatic hyper-CK-emia: An electrophysiologic and histopathologic study. Muscle Nerve. 1989;12:206-209.
90. Weglinski MR, Wedel DJ, Engel AG. Malignant hyperthermia testing in patients with persistently increased serum creatine kinase levels. Anesth Analg. 1997;84:1038-1041.
91. Gabow PA, Kaehny WD, Kelleher SP. The spectrum of rhabdomyolysis. Medicine. 1982;61:141-152.
92. Al-Shekhlee A, Hachwi R, Jaberi MM, et al. The electromyographic features of acute rhabdomyolysis. J Clin Neuromuscul Dis. 2005;6:114-118.
93. Figarella-Branger D, Kozak-Ribbens G, Rodet L, et al. Pathological findings in 165 patients explored for malignant hyperthermia susceptibility. Neuromuscul Disord. 1993;3:553-556.